William L. Pridgen, MD, Chief Executive Officer
Dr. Pridgen is Board Certified in General Surgery, a Fellow of the American College of Surgeons, and for nearly two decades has conducted research into the causes of chronic pain, IBS, ME/CFS, fibromyalgia, and other chronic idiopathic disorders. Before founding IMC, Dr. Pridgen treated thousands of patients with fibromyalgia and chronic gastrointestinal issues, and was determined to gain a better scientific understanding of the sporadic, unpredictable recurrences of his patients' discomforts. His quest for answers served as the catalyst for Dr. Pridgen’s viral theory, leading to his utilization of anti-viral combinations that consistently resulted in positive outcomes for his patients. These positive outcomes served as the inspiration for IMC. Dr. Pridgen has a Bachelor of Science degree from Rhodes College, received his medical degree from the University of Tennessee (where he served his residency from 1988-1993, ultimately becoming Chief Resident), and served his country for five years in the US Navy as a general medical officer and surgeon.
Rick Burch, President
Prior to joining IMC, Mr. Burch had a 30-year career with the pharmaceutical giant Pfizer, starting as a sales rep and working his way up to Senior Vice President overseeing numerous divisions with more than 6,500 employees. He was accountable for $11.5 billion in revenue and had responsibilities in launching over 20 pharmaceutical products, including blockbuster brands such as Celebrex, Lyrica, Aricept, and Lipitor. Following his highly successful tenure at Pfizer, Mr. Burch was named Vice President and General Manager for UCB, Inc., overseeing all operations for the US CNS Business Unit including P&L management and responsibility for pipeline and in-line portfolio of CNS products. Mr. Burch currently serves on the Executive Committee of the University of Alabama Business School Board and is a member of the University of Alabama President’s Cabinet, as well as the University of Florida School of Pharmacy Board. Mr. Burch received a Bachelor’s Degree in Marketing from the University of Alabama and certification from the Finance and Accounting Department of Columbia University’s Graduate School of Business.
Carol Duffy, PhD, Chief Scientific Advisor
Dr. Duffy is a highly accomplished, widely published expert in virology who has focused her efforts on HSV-1. Dr. Duffy’s research has been critical to IMC in the development of a highly sophisticated understanding of the HSV-1 replication cycle as well as mechanisms by which HSV-1 infection and reactivation can be controlled. Dr. Duffy received a PhD in Microbiology from the University of Iowa in 2000 and completed her postdoctoral research at Cornell University. She was appointed Assistant Professor at the University of Alabama in 2007 and was promoted to Associate Professor with Tenure in 2013.
R. Michael Gendreau, MD, PhD
Dr. R. Michael Gendreau has spent over 30 years in the biomedical and pharmaceutical industries, with over 20 years of experience serving as a Chief Medical Officer and/or VP of R&D for small, nimble biotechnology companies. Dr. Gendreau has a proven track record of FDA approvals for diagnostic systems (Affirm™ VP), medical devices (Prosorba® Column), and therapeutics (Savella®). As one of the early founders of Cypress Bioscience, Dr. Gendreau served as the Chief Medical Officer for all development programs and subsequent FDA approvals of the Prosorba® Column for rheumatoid arthritis and Savella® for management of fibromyalgia. Dr. Gendreau serves as a consulting Chief Medical Officer for multiple pharmaceutical companies, including serving as the acting Chief Medical Officer for the IMC-1 development program.
Dr. Gendreau is a graduate of the Ohio State University MD/ PhD (pharmacology) program.
Judith Gendreau, MD
Dr. Judith Gendreau has spent over 20 years in the biomedical and pharmaceutical industries with responsibilities encompassing clinical research and development, medical monitoring, pharmacovigilance, medical writing, and medical affairs. At Cypress Bioscience, Dr. Gendreau served as the lead study physician and Chief Safety Officer for all development programs and subsequent FDA approvals of the Prosorba® Column for rheumatoid arthritis and Savella® for management of fibromyalgia. Since Cypress was purchased in 2010, she has served as a “study physician for hire,” and has worked on multiple clinical development programs, including serving as the day-to-day study physician and medical monitor for the IMC-1 development program.
After graduation from the Ohio State University College of Medicine, she entered an internal medicine residency, followed by 3 years of general medical practice, before moving into full-time research.
Merrill R. Osheroff, PhD, DABT
Dr. Osheroff received his doctorate from the University of Wisconsin-Madison in Pathology and Experimental Medicine and has 35 years of experience in the field of regulatory toxicology and drug development. Since 2007, his company, Osheroff Consulting Services, has been providing clients expertise in numerous aspects of drug development planning and strategy including regulatory submissions, due diligence of compounds for in-licensing, nonclinical studies and CRO qualification/outsourcing and is actively engaged in project management to guide his clients to meet successful regulatory goals.
Prior to forming Osheroff Consulting Services, Dr. Osheroff served in many high-level management positions including Senior Program Director at the Battelle Memorial Institute in Columbus, OH; Executive Director and Site Head, Worldwide Safety Sciences-Kalamazoo at the Pfizer Corporation in Kalamazoo, MI; Director of MSE-Newstead and Director of Global Preclinical Outsourcing for Pharmacia Corporation in St. Louis, MO and Kalamazoo, MI. He is a past President of the American College of Toxicology and an active member/Treasurer of the Roundtable of Toxicology Consultants.
Leah Appel, PhD
Leah Appel has more than 20 years experience in the pharmaceutical industry, with extensive experience developing drug delivery technology and products. She has applied her expertise across the entire range of drug product development, both tailoring novel delivery technologies for clinical applications and reducing delivery technologies to practice. She is an inventor on 35 drug delivery patents and patent applications and was recently appointed to a 3 year term as scientific advisor to the Journal of Pharmaceutical Sciences. Her primary area of expertise is in oral solid dosage forms including controlled release and delivery of insoluble compounds. Leah obtained her BS in Chemical Engineering from UCLA in 1982, and her Ph.D. in Pharmaceutics from the University of Utah in 1988. Prior to founding Green Ridge Consulting in 2007, she worked for 10 years at Bend Research, Inc. as the Director of Controlled Release and for 7 years at INTERx (a division of Merck), developing controlled release technologies.
Ben Bonifant is an experienced consultant to leaders of global pharmaceutical and biotechnology organizations, and to decision makers of large private equity funds. Prior to the founding of Triangle Insights Group, Ben was the leader of the Business Development Practice at Campbell Alliance and a partner in the Strategy Practice at Oliver Wyman (formerly Mercer Management Consulting/Strategic Planning Associates). Ben earned an MBA from the Stanford Graduate School of Business and a BS from Duke University.
Ben has been a management consultant for more than 20 years. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals. Recent by-lined articles have appeared in Pharmaceutical Executive, InVivo, Nature Biotech, RPM Report and Scrip. In addition, Ben's case studies on the pharmaceutical industry have been used in graduate business programs.
Ben is a member of the Life Sciences Executive Committee of the Licensing Executive Society. He has also been a member of the program committee for the BIO International Convention. Ben has been a guest lecturer at Duke's Fuqua School of Business, the Indiana University Kelley School of Business, and industry conferences in the US, Europe, and Canada.
Kevin A. Phelan, PhD
Dr Kevin A. Phelan has more than 20 years of experience in regulatory affairs and clinical development, including the development of treatments for fibromyalgia. Dr Phelan works extensively in the areas of pain, inflammation, and neuroscience, in addition to a variety of other therapeutic areas. He advises companies on Phase I-IV regulatory strategies, FDA interactions, and IND/NDA preparations. Prior to consulting and working with IMC, he had a 20-year career at Pfizer in Global Research and Development, Clinical Development, and Worldwide Regulatory Affairs. Dr Phelan earned a PhD in Neurobiology from The University of Chicago.
Frank Deane, Ph.D.
Frank Deane is the Founder and a Director of Lumleian, LLC. Frank has over ten years of experience working with life science companies, having worked at Leerink Swann, Bain & Company, BlackRock, Inc., and Eli Lilly, where he specialized in portfolio optimization and business unit strategic planning. As a consultant, Frank has worked with global pharmaceutical companies, biotechnology companies, and life science investors on portfolio optimization, clinical development benchmarking, commercial and clinical diligence, primary research and valuation analysis, early and late stage pipeline development strategy, and forecasting. Frank earned his Ph.D. in econometrics from the Krannert School of Management at Purdue University, where his dissertation focused on applying game theory and statistical modeling to optimize pharmaceutical resource allocation. Frank earned his B.A. in Economics from Princeton University. In addition, Frank co-teaches a course on strategic issues in the pharmaceutical industry at the Boston College Carroll School of Management.
Jason Greenberg, Esq.
Jason Greenberg is General Counsel and a Director of Lumleian, LLC. Jason has over eight years working in the life sciences industry, advising public and private companies on a variety of legal, regulatory, and business issues. Prior to joining Lumleian, Jason worked for Sassoon & Cymrot, LLP, Fried Frank Harris Shriver and Jacobson, as a judicial clerk at the U.S. District Court in Boston, and for Senator John Warner (R-VA) in Legislative and Regulatory Affairs. As a consultant, Jason has worked with top global pharmaceutical companies, biotechnology companies, and life science investors on portfolio strategy, early and late stage asset targeting/development strategy, licensing and partnering strategy and negotiation, intellectual property, clinical, and commercial diligence, market access and pricing/reimbursement strategy, and clinical development strategy. Jason earned his J.D. from Suffolk University Law School and earned his B.A. in Political Science from George Washington University. In addition, Jason co-teaches a course on strategic issues in the pharmaceutical industry at the Boston College Carroll School of Management.